Sernova Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SEOVF research report →
Price Chart
About the company
Sernova Corp. is a Canadian firm, established in 1998 and headquartered in London, that specializes in advanced regenerative medicine therapeutics and is currently in its clinical development phase. The company's primary objective is to innovate and bring to market novel treatments, with a core focus on its unique "Cell Pouch" system.
- CEO
- Jonathan N. Rigby
- IPO
- 2007
- Employees
- 8
- HQ
- Mississauga, ON, CA
Get TickerSpark's AI analysis on SEOVF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $30.21M
- P/E
- -3.91
- Fwd P/E
- 0.51
- PEG
- -0.05
- P/S
- 0.00
- P/B
- -3.69
- EV/EBITDA
- -5.10
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 57.10%
- ROIC
- 95.68%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-342,544+0.0%
- Op Income
- $-15,023,024
- Net Income
- $-15,741,351+51.1%
- EPS
- $-0.05+52.1%
- OCF Growth
- +42.3%
- FCF Growth
- +42.3%
- 52W High
- $0.14
- 52W Low
- $0.06
- 50D MA
- $0.08
- 200D MA
- $0.10
- Beta
- 0.64
- RSI (14)
- 53
- Avg Volume
- 87.71K
No earnings-call transcripts are available for SEOVF yet.
- Free Float
- 86.5%
- Shares Outstanding
- 377.64M
- Float Shares
- 326.77M
Our SEOVF coverage
Recent articles, reports, and earnings notes.
No research on SEOVF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SEOVF report →Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial
globenewswire.com · Oct 5
Sernova Biotherapeutics to Participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference
globenewswire.com · Sep 25
Sernova Biotherapeutics Announces Closing of Recently Approved Financings
newsfilecorp.com · Apr 23
Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders
newsfilecorp.com · Apr 9
Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing
newsfilecorp.com · Mar 24
Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to Shareholder Approval
newsfilecorp.com · Mar 4
Sernova Biotherapeutics Announces Warrant Amendments
newsfilecorp.com · Feb 20
Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang
newsfilecorp.com · Oct 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.